Final remit: To appraise the clinical and cost effectiveness of imlifidase within its marketing authorisation for desensitisation treatment before kidney transplantation in highly sensitised people with chronic kidney disease.
Status In progress
Process STA 2018
ID number 1672

Project Team

Project lead Gavin Kenny

Email enquiries


Companies sponsors Hansa Biopharma (imlifidase)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Professional groups British Transplantation Society
  Renal Association
  Royal College of Physicians


General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
01 April 2021 NICE requires further information and additional analyses to be completed. Therefore, NICE has paused this appraisal pending further work
11 March 2021 Committee meeting: 1
11 May 2020 Invitation to participate
08 May 2020 In progress
06 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
17 January 2020 (10:00) Scoping workshop (Manchester)
14 November 2019 - 12 December 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance